Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

LEUKEMIA & LYMPHOMA

Doubek, M; Trbusek, M; Malcikova, J; Brychtova, Y; Smardova, J; Lochmanova, J; Panovska, A; Francova, HS; Mraz, M; Tichy, B; Sebejova, L; Navrkalova, V; Plevova, K; Kuglik, P; Mayer, J; Pospisilova, S, 2012: Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 53(9), p. 1817 - 1819, doi: 10.3109/10428194.2012.658794

Research Groups:

CF: Genomics Core Facility

CEITEC authors:

Prof. Marek Mráz, Ph.D.
Prof. Šárka Pospíšilová, Ph.D.
Boris Tichý, Ph.D.
Prof. Jiří Mayer